Abstract
Therapy for Hodgkin's disease has been associated with a significant increase in risk for second cancers. To begin an investigation of the association of therapy-induced genetic damage with this risk, somatic mutations at the hypoxanthine phosphoribosyltransferase locus were measured in lymphocytes from patients previously treated for Hodgkin's disease. The results demonstrate that a subset of patients have persistently elevated mutation frequencies, perhaps suggesting that these individuals are among those at significant risk of second cancer development.
Original language | English (US) |
---|---|
Pages (from-to) | 353-367 |
Number of pages | 15 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 7 |
Issue number | 2 |
DOIs | |
State | Published - 1993 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology
- Oncology